
ALC Stock Forecast & Price Target
ALC Analyst Ratings
Bulls say
Alcon is set to benefit from an earlier than expected allergy season, which could bring a boost in sales for its allergy medication Pataday, a key driver in its Ocular Health segment. The company has a strong presence in the visioncare market with its popular brands like Dailies and Total1, and has a dominant position in the US contact lens market. Alcon has a consistent track record of delivering top-line growth and innovative products, and its end-markets are expected to improve in the early part of FY26 due to new product launches. With a solid growth profile and steady operating margin expansion, Alcon is positioned for growth and its valuation remains favorable compared to its historical average. Some key risks to this outlook include a weaker economy, delays in product rollouts, and increased competition in its various business segments.
Bears say
Alcon is facing competition in both its visioncare and surgical segments and has not seen the strong growth previously anticipated from new products in the market. Despite having one of the largest installed bases of eye surgical equipment and a portfolio of IOLs, operating margins have not expanded significantly and costs continue to grow, leaving shares range-bound and likely unable to support their premium valuation. Additionally, although Alcon operates in a large market with the potential for growth through new treatment options, there is high competition and the potential for weaker-than-expected uptake of these new products, resulting in lower-than-expected growth.
This aggregate rating is based on analysts' research of Alcon Inc. - Registered Shares and is not a guaranteed prediction by Public.com or investment advice.
ALC Analyst Forecast & Price Prediction
Start investing in ALC
Order type
Buy in
Order amount
Est. shares
0 shares